Nothing Special   »   [go: up one dir, main page]

Zhu et al., 2006 - Google Patents

Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses

Zhu et al., 2006

View PDF
Document ID
4169976679932991081
Author
Zhu Z
Dimitrov A
Chakraborti S
Dimitrova D
Xiao X
Broder C
Dimitrov D
Publication year
Publication venue
Expert review of anti-infective therapy

External Links

Snippet

Polyclonal antibodies have a century-old history of being effective against some viruses; recently, monoclonal antibodies (mAbs) have also shown success. The humanized mAb Synagis®(palivizumab), which is still the only mAb against a viral disease approved by the …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • C07K16/1027Paramyxoviridae, e.g. respiratory syncytial virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2316/00Immunoglobulins specific features
    • C07K2316/96Antibodies with antagonisticactivity upon their specific binding to an antigen

Similar Documents

Publication Publication Date Title
Clark et al. SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms
Sun et al. Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2
Zhao et al. Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability
Pantaleo et al. Antibodies to combat viral infections: development strategies and progress
Widjaja et al. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein
Salazar et al. Antibody therapies for the prevention and treatment of viral infections
Sui et al. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness
Wu et al. Single-domain antibodies as therapeutics against human viral diseases
Li et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein
CN107667115B (en) Human antibodies to ebola virus glycoproteins
Howell et al. Cooperativity enables non-neutralizing antibodies to neutralize ebolavirus
Fels et al. Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever
Coughlin et al. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential
Ter Meulen et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants
Both et al. Monoclonal antibodies for prophylactic and therapeutic use against viral infections
Xia et al. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein
JP5808536B2 (en) Anti-RSVG protein antibody
Allen et al. A protective monoclonal antibody targets a site of vulnerability on the surface of Rift Valley fever virus
Crowe Jr Human antibodies for viral infections
Prabakaran et al. Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses
Williams et al. A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo
Milligan et al. Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses
Xu et al. The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization
Strohl et al. Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants
Sroga et al. Nanobodies: a new approach for the diagnosis and treatment of viral infectious diseases